Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 20/20 | 0.68 |
| ▸ | EZH1 | Q92800 | 3/20 | 0.63 |
| ▸ | EED | O75530 | 2/20 | 0.63 |
| ▸ | RBBP4 | Q09028 | 2/20 | 0.63 |
| ▸ | SUZ12 | Q15022 | 2/20 | 0.63 |
| ▸ | AEBP2 | Q6ZN18 | 2/20 | 0.63 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.63 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.63 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.63 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.63 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15710175 | 0.96 | EZH2 (0.69) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL15700452 | 0.93 | EZH2 (0.61) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL17148711 | 0.93 | EZH2 (0.61) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL15709969 | 0.92 | EZH2 (0.69) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL17136172 | 0.91 | EZH2 (0.74) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL15700453 | 0.91 | EZH2 (0.74) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL15700448 | 0.90 | EZH2 (0.60) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL17148710 | 0.89 | EZH2 (0.62) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL15700512 | 0.89 | EZH2 (0.62) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL17136251 | 0.87 | EZH2 (0.75) | EZH2EZH1EEDRBBP4SUZ12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11642348-B2 | Substituted benzene compounds | Epizyme, Inc. (US) | 2023-05-09 | — | — | US | disclosed |
| EP-3725314-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2020-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11642348-B2 | Substituted benzene compounds | CYP1B1, TP53, VHL | EZH2 2519/4885EZH1 1276/4885EED 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.